Kiniksa Pharmaceuticals Ltd (KNSA) FinancialsKNSAKiniksa Pharmaceuticals Ltd

Evaluating the bottom line, Kiniksa Pharmaceuticals International, PLC maintains a gross margin of 90.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 11.16%, while the net margin is 10.44%. These profitability ratios, combined with a Return on Equity (ROE) of 14.04%, provide a clear picture of how effectively KNSA converts its operational activities into shareholder value.

In the context of the broader market, KNSA competes directly with industry leaders such as BLTE and LQDA. With a market capitalization of $5.99B, it holds a significant position in the sector. When comparing efficiency, KNSA's gross margin of 90.32% stands against BLTE's N/A and LQDA's 93.27%. Such benchmarking helps identify whether Kiniksa Pharmaceuticals International, PLC is trading at a premium or discount relative to its financial performance.

Kiniksa Pharmaceuticals has shown impressive financial performance, with a gross margin of 90.32% in Q2 2026 and a net income of $25.4 million, marking a 43% increase year-over-year. The company has also consistently improved its revenue, with total revenue increasing from $112.2 million in Q3 2024 to $243.6 million in Q2 2026.